INT2408

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.61
First Reported 1979
Last Reported 2010
Negated 7
Speculated 5
Reported most in Abstract
Documents 37
Total Number 42
Disease Relevance 10.01
Pain Relevance 26.66

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (CCK) extracellular space (CCK) extracellular region (CCK)
Anatomy Link Frequency
plasma 8
pancreas 4
eyes 2
lymphocytes 2
muscle 1
CCK (Homo sapiens)
Pain Link Frequency Relevance Heat
Cholecystokinin 522 100.00 Very High Very High Very High
Pain 86 100.00 Very High Very High Very High
antagonist 84 100.00 Very High Very High Very High
Bile 34 100.00 Very High Very High Very High
Neurotransmitter 18 100.00 Very High Very High Very High
Analgesic 17 100.00 Very High Very High Very High
narcan 12 100.00 Very High Very High Very High
opiate 11 100.00 Very High Very High Very High
Enkephalin 10 100.00 Very High Very High Very High
5HT 5 100.00 Very High Very High Very High
Disease Link Frequency Relevance Heat
Diabetes Mellitus 9 99.62 Very High Very High Very High
Pancreatitis 37 99.40 Very High Very High Very High
Pain 78 99.12 Very High Very High Very High
Dyspepsia 114 98.84 Very High Very High Very High
Depression 4 98.00 Very High Very High Very High
Critical Illness 182 97.80 Very High Very High Very High
Anxiety Disorder 4 97.40 Very High Very High Very High
Exocrine Pancreatic Insufficiency 1 96.80 Very High Very High Very High
Pancreatic Cancer 2 96.40 Very High Very High Very High
Irritable Bowel Syndrome /

Irritable Bowel Syndrome Super

216 95.68 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
This clonal neuronal cell line provides a unique model system to identify cis- and trans-acting factors responsible for neuron-specific expression and regulation of the CCK gene.
Regulation (regulation) of CCK in neuron associated with cholecystokinin
1) Confidence 0.61 Published 1990 Journal FEBS Lett. Section Abstract Doc Link 2384178 Disease Relevance 0.16 Pain Relevance 0.63
Somatostatin has been used in many studies in the therapy of pain in chronic pancreatitis and plays a role in the regulation of cholecystokinin levels, however data on its plasma levels are still lacking.
Regulation (regulation) of cholecystokinin in plasma associated with pain, cholecystokinin and chronic pancreatitis
2) Confidence 0.61 Published 2000 Journal Hepatogastroenterology Section Abstract Doc Link 10919050 Disease Relevance 0.36 Pain Relevance 0.63
Camostat did not influence plasma cholecystokinin levels.
Neg (not) Regulation (influence) of cholecystokinin in plasma associated with cholecystokinin
3) Confidence 0.59 Published 1997 Journal J. Gastroenterol. Section Abstract Doc Link 9213253 Disease Relevance 0.33 Pain Relevance 0.33
Similarly, previous reports indicate that intravenous lipid has no effect on plasma CCK concentrations [37-39].
Neg (no) Regulation (effect) of CCK in plasma associated with cholecystokinin
4) Confidence 0.59 Published 2006 Journal Crit Care Section Body Doc Link PMC1794491 Disease Relevance 0.34 Pain Relevance 0.21
Effects of cholecystokinin and caerulein on human eating behavior and pain sensation: a review.
Regulation (Effects) of cholecystokinin associated with pain, analgesic and cholecystokinin
5) Confidence 0.45 Published 1986 Journal Psychoneuroendocrinology Section Title Doc Link 3085129 Disease Relevance 0.23 Pain Relevance 0.87
Human studies have now confirmed the pro-analgesic effect of some CCK antagonists.
Regulation (effect) of CCK associated with antagonist and analgesic
6) Confidence 0.45 Published 2004 Journal Curr. Pharm. Des. Section Abstract Doc Link 14754389 Disease Relevance 0.08 Pain Relevance 1.63
This review examines the available evidence that suggests a role for CCK antagonists in human pain management.
Regulation (role) of CCK associated with antagonist and pain management
7) Confidence 0.45 Published 2004 Journal Curr. Pharm. Des. Section Abstract Doc Link 14754389 Disease Relevance 0.17 Pain Relevance 1.56
Human investigation of the effect of CCK antagonists on analgesic tolerance has yet to be performed.
Regulation (effect) of CCK associated with analgesic, antagonist and tolerance
8) Confidence 0.45 Published 2004 Journal Curr. Pharm. Des. Section Abstract Doc Link 14754389 Disease Relevance 0.08 Pain Relevance 1.62
In the present study, we investigated the effects of the opiate antagonist naloxone and the cholecystokinin antagonist proglumide on placebo analgesia in a human model of experimentally induced ischemic pain.
Spec (investigated) Regulation (effects) of cholecystokinin associated with pain, antagonist, narcan, opiate, cholecystokinin and analgesia
9) Confidence 0.45 Published 1996 Journal Pain Section Abstract Doc Link 8783319 Disease Relevance 0.10 Pain Relevance 1.34
Second, since it was demonstrated that the action of exogenous and endogenous opiates is potentiated by proglumide, we analysed the effects of this cholecystokinin antagonist on placebo response and found that it enhanced placebo analgesia.
Spec (analysed) Regulation (effects) of cholecystokinin associated with antagonist, opiate, cholecystokinin and analgesia
10) Confidence 0.45 Published 1996 Journal Pain Section Abstract Doc Link 8783319 Disease Relevance 0.09 Pain Relevance 1.48
The contractile effects of cholecystokinin (CCK) on iris sphincter and ciliary muscles from monkey and human eyes were studied using an isolated smooth muscle bath.
Regulation (effects) of cholecystokinin in eyes associated with cholecystokinin
11) Confidence 0.45 Published 1992 Journal Eur. J. Pharmacol. Section Abstract Doc Link 1612109 Disease Relevance 0 Pain Relevance 0.47
The contractile effects of cholecystokinin (CCK) on iris sphincter and ciliary muscles from monkey and human eyes were studied using an isolated smooth muscle bath.
Regulation (effects) of CCK in eyes associated with cholecystokinin
12) Confidence 0.45 Published 1992 Journal Eur. J. Pharmacol. Section Abstract Doc Link 1612109 Disease Relevance 0 Pain Relevance 0.47
The evidence that has established the involvement of gastrin/CCK(B)-R in mediating the action of hypergastrinaemic disorders, mediating hypergastrinaemic effects on the gastric mucosa (ECL hyperplasia, carcinoids, parietal cell mass), and acid-peptic diseases, is reviewed.
Regulation (involvement) of CCK in parietal cell associated with carcinoid, disease, cholecystokinin and hyperplasia
13) Confidence 0.45 Published 2002 Journal Pharmacol. Toxicol. Section Abstract Doc Link 12688377 Disease Relevance 0.91 Pain Relevance 0.57
This review will highlight the results from both basic and clinical investigations that have examined the effects of selective CCK receptor ligands.
Spec (examined) Regulation (effects) of CCK
14) Confidence 0.45 Published 1994 Journal Pharmacol. Ther. Section Abstract Doc Link 7972336 Disease Relevance 0 Pain Relevance 0.21
The integrated changes in plasma concentrations of CCK and PYY were calculated and expressed as areas under the curve over the 120 minutes (AUC0–120 min) after the Ensure meal.
Regulation (changes) of CCK in plasma associated with cholecystokinin
15) Confidence 0.45 Published 2007 Journal Crit Care Section Body Doc Link PMC2246231 Disease Relevance 0.08 Pain Relevance 0.19
Devazepide, the cholecystokinin (CCK) A receptor blocker, markedly and specifically affected the behavior of 10-day-old rats isolated from their mother and siblings.
Regulation (affected) of cholecystokinin associated with cholecystokinin
16) Confidence 0.44 Published 1993 Journal Behav. Neurosci. Section Abstract Doc Link 8329138 Disease Relevance 0.07 Pain Relevance 0.37
The results of studies on the effects of CCK-8 and the decapeptide analogue caerulein on pain thresholds are conflicting.
Regulation (effects) of CCK associated with pain
17) Confidence 0.43 Published 1989 Journal Pain Section Abstract Doc Link 2694075 Disease Relevance 0.46 Pain Relevance 1.09
A CCK challenge test has been used to test the response to CCK.
Regulation (response) of CCK associated with cholecystokinin
18) Confidence 0.40 Published 2010 Journal Journal of Neurogastroenterology and Motility Section Body Doc Link PMC2912117 Disease Relevance 0.32 Pain Relevance 0.79
Dexloxiglumide has a potent antagonistic effect, of a competitive nature, on human gallbladder cholecystokinin type 1 receptors.
Regulation (effect) of cholecystokinin associated with cholecystokinin
19) Confidence 0.37 Published 2003 Journal Minerva Gastroenterol Dietol Section Abstract Doc Link 16484960 Disease Relevance 0 Pain Relevance 0.27
There was a significant rise in pancreatic polypeptide compared to a control infusion, but no change in plasma insulin, pancreatic glucagon, gastrin, somatostatin, motilin, neurotensin, gastric inhibitory peptide, or cholecystokinin was seen.
Neg (no) Regulation (change) of cholecystokinin in plasma associated with somatostatin and cholecystokinin
20) Confidence 0.35 Published 1984 Journal Clin. Endocrinol. (Oxf) Section Abstract Doc Link 6147213 Disease Relevance 0 Pain Relevance 0.19

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox